"CSL Behring has a long history of providing medical innovations and supportive services, like the JNC and My Source, that make a meaningful difference in the lives of those with a bleeding disorder and those who care for them," said Bill Campbell, Senior Vice President, North America Commercial Operations, CSL Behring. "We congratulate William and Nicholas and all of the competitors on their tremendous accomplishments during the event and throughout the year. CSL Behring’s commitment to the community is long-standing and the JNC demonstrates our team’s passion for what they do."
CSL Behring's JNC program is the first and only national golf and baseball competition designed specifically for the bleeding disorders community. In addition to the competitive activities, this event provides children and their caregivers with educational information and opportunities to interact with others in the community.
"CSL Behring understands that it can be helpful for members of the bleeding disorders community to interact with others who face similar challenges," said Kim Phelan, Vice President, The Coalition for Hemophilia B. "CSL Behring's programs, like the JNC, allow our members to make connections with those who share similar experiences, and we greatly appreciate these opportunities."
In addition to naming national golf and baseball champions, CSL Behring recognized Chase Tulledge from Hemophilia of Indiana as the event’s national raffle winner. For more information about the JNC program or the wide variety of resources for the bleeding disorders community offered by CSL Behring, please visit www.MySourceCSL.com or call 1-800-676-4266. CSL Behring’s My Source program provides one-stop access to educational information, financial support and community connections to individuals living with hemophilia and/or VWD.About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a global biopharmaceutical company and a member of the CSL Group of companies. The parent company, CSL Limited (ASX:CSL), is headquartered in Melbourne, Australia. For more information, visit http://www.cslbehring.com/.